AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/06/22

Summary Aurinia has been facing many problems. Potential sales chatter may be a result of its problems. However, I see little reason for big pharma to buy AUPH. Aurinia’s ( AUPH ) price movement over the last 12 months seems predicated on 3 things - key ma...

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Ed Arce - H...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock are down 30% today after the company reported its latest financial results and lowered its forward guidance. AUPH stock is one of the top trending tickers on S...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) lost ~22% pre-market Thursday even after announcing better-than-expected financials for Q3 2022 as the company lowered its full-year guidance citing weak demand for lupus nephritis therapy Lupkynis. “Un...

Aurinia Pharma press release ( NASDAQ: AUPH ): Q3 GAAP EPS of -$0.06 beats by $0.13 . Revenue of $55.78M (+280.5% Y/Y) beats by $19.38M . “During the third quarter, we demonstrated progress across many key commercial metrics for LUPKYNIS, including an in...

Net revenue of $55.8 million for Q3 2022; including $30.0 million milestone from Otsuka related to European Approval of LUPKYNIS ® (voclosporin) Adjusts net product revenue guidance to $100-105 million from sales of LUPKYNIS for 2022 Issues preliminary net...

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.19 (+51.3% Y/Y) and the consensus Revenue Estimate is $36.4M (+148.3% Y/Y). Over the last 1 year, AUPH has be...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter 2022 on Thursday, November 3, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at ...

Aurinia Stock ( NASDAQ:AUPH ) Aurinia Pharmaceuticals ( NASDAQ:AUPH ), a Canadian biotech company, has fallen back into the red just one day after posting a gain of approximately 13%. This comes at the same time that H.C. Wainwright has taken steps to address...

Just a day after a ~13% rise, Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) is back in the red even as H.C. Wainwright moved to address questions surrounding the departures of the company's Chief Medical Officer and Executive Vice President of Research. The r...